1-(4-异丁氧基苯基)乙酮 | 24242-97-5

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(4-异丁氧基苯基)乙酮
• 英文名称: 1-(4-isobutoxyphenyl)ethanone
• 英文别名: p-(iso-Butyloxy)-phenylacetyl；1-(4-Isobutoxy-phenyl)-aethanon；4'-(2-methylpropyloxy)acetophenone；1-[4-(2-methylpropoxy)phenyl]ethanone
• CAS: 24242-97-5
• 化学式: C₁₂H₁₆O₂
• mdl: MFCD00995652
• 分子量: 192.258
• InChiKey: ACRYHNAGXRLMAC-UHFFFAOYSA-N

物化性质

• 沸点：
  149-151 °C(Press: 10 Torr)
• 密度：
  0.986±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2914509090
• 储存条件：
  | 室温 |

反应信息

• 作为反应物：
  描述：

  1-(4-异丁氧基苯基)乙酮 在 copper(ll) bromide 作用下， 以 氯仿 、 乙酸乙酯 为溶剂， 反应 2.0h， 以89%的产率得到α-bromo-4'-isobutoxyacetophenone
  参考文献：
  名称：

  Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

  摘要：

  GnRH受体拮抗剂已被披露，可用于治疗男性和女性的各种与性激素相关的疾病。该发明的化合物具有以下结构：包括立体异构体、前药和其药用盐，其中Ar、B、R1、R2、R3a、R3b、R4、R5、R6和m的定义如本文所述。

  公开号：

  US06346534B1
• 作为产物：
  描述：

  (isobutyloxy)benzene 、 乙酸酐 在 ferric hydrogen sulfate 作用下， 以 硝基甲烷 为溶剂， 反应 5.0h， 以69%的产率得到1-(4-异丁氧基苯基)乙酮
  参考文献：
  名称：

  硫酸氢铁催化Friedel-Crafts酰化烷氧基苯

  摘要：

  摘要 在硝基甲烷中，在催化量的硫酸氢铁 Fe(HSO4)3 存在下，通过与脂肪酸酐反应，可以有效地实现烷氧基苯的 Friedel-Crafts 酰化。烷基苯和芳基卤化物以及芳香酸酐在这些条件下保持完整。

  DOI：

  10.1081/scc-120018697

文献信息

• Catalytic Friedel–Crafts Acylation of Alkoxybenzenes Mediated by Aluminum Hydrogensulfate in Solution and Solvent-Free Conditions
  作者：Peyman Salehi、Mohammad Mehdi Khodaei、Mohammad Ali Zolfigol、Sara Sirouszadeh

  DOI：10.1246/bcsj.76.1863

  日期：2003.9

  Friedel–Crafts acylation of alkoxybenzenes was achieved efficiently by a reaction with aliphatic acid anhydrides in the presence of catalytic amounts of aluminum hydrogensulfate, Al(HSO4)3, in nitromethane and under solvent-free conditions. Alkylbenzenes and aryl halides, as well as aromatic anhydrides, remained intact under these conditions.

  在催化量的硫酸氢铝 Al(HSO4)3 存在下，在硝基甲烷和无溶剂条件下，通过与脂肪酸酐反应，有效地实现烷氧基苯的 Friedel-Crafts 酰化。在这些条件下，烷基苯和芳基卤化物以及芳族酸酐保持完整。
• Design, Synthesis, Biological Evaluation and Inhibition Mechanism of 3-/4-Alkoxy Phenylethylidenethiosemicarbazides as New, Potent and Safe Tyrosinase Inhibitors
  作者：Senchuan Song、Yuliang Mai、Huahong Shi、Bing Liao、Fei Wang

  DOI：10.1248/cpb.c19-00949

  日期：2020.4.1

  Tyrosinase plays important roles in many different disease related processes, and the development of its inhibitors is particularly important in biotechnology. In this study, thirty-nine 3-/4-alkoxyphenylethylidenethiosemicarbazides were synthesized as novel tyrosinase inhibitors based on structure-based molecular design. Our experimental results demonstrated that thirty-one of them possess remarkable tyrosinase inhibitory activities with IC50 value below 1 µM, and 5a, 6e, 6g and 6t did not display any toxicity to 293T cell line at the concentration of 1000 µmol/L. According to the inhibitory activities, several compounds were selected for detail investigation on the structure–activity relationships (SARs), mechanisms of enzyme inhibition, inhibitory kinetics and cytotoxicity. In particular, the interaction between the selected inhibitors and the active center of tyrosinase was considered and discussed in detail based on their structural characteristics. Taken together, the results presented here demonstrated that the newly designed compounds are promising candidates for the treatment of tyrosinase-related disorders and further development of them may have significant contribution in biomedical science.

  酪氨酸酶在多种与疾病相关的过程中扮演重要角色，其抑制剂的研发在生物技术领域尤为重要。本研究基于结构导向的分子设计，合成了39种新颖的3-/4-烷氧基苯乙烯基二唑半卡巴唑类化合物作为酪氨酸酶抑制剂。我们的实验结果显示，其中31种化合物的酪氨酸酶抑制活性显著，IC50值低于1µM，且5a、6e、6g和6t在1000µmol/L浓度下对293T细胞系无毒性。根据抑制活性，选取了若干化合物详细研究了构效关系、酶抑制机制、抑制动力学及细胞毒性。特别是，基于这些化合物的结构特征，详细考虑并讨论了所选抑制剂与酪氨酸酶活性中心的相互作用。综上所述，本研究结果表明，新设计的化合物是治疗与酪氨酸酶相关疾病的潜在候选药物，其进一步开发可能对生物医学科学产生重大贡献。
• HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase
  作者：Johan Evenäs、Fredrik Edfeldt、Matti Lepistö、Naila Svitacheva、Anna Synnergren、Britta Lundquist、Mia Gränse、Anna Rönnholm、Mikael Varga、John Wright、Min Wei、Sherrie Yue、Junfeng Wang、Chong Li、Xuan Li、Gang Chen、Yong Liao、Gang Lv、Ann Tjörnebo、Frank Narjes

  DOI：10.1016/j.bmcl.2014.01.050

  日期：2014.3

  based inhibitors of xanthine oxidase is described. After a high-throughput screening campaign, an NMR based counterscreen was used to distinguish actives, which interact with XO in a reversible manner, from assay artefacts. This approach identified pyrimidone 1 as a reversible and competitive inhibitor with good lead-like properties. A hit to lead campaign gave compound 41, a nanomolar inhibitor of hXO

  描述了新型，非嘌呤的黄嘌呤氧化酶抑制剂的鉴定。经过高通量筛选活动后，基于NMR的反筛选用于区分活性物，这些活性物以可逆方式与XO相互作用，与分析伪像分离。该方法将嘧啶酮1鉴定为可逆的竞争性抑制剂，具有良好的铅样性质。导致先头运动获得化合物41，一种hXO的纳摩尔抑制剂，口服给药后在高尿酸血症大鼠模型中具有功效。
• N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES
  申请人：GRIFFIOEN Gerard

  公开号：US20100197703A1

  公开（公告）日：2010-08-05

  This invention provides thiazolylpiperazine derivatives, and N-sulfonyl heterocyclic derivatives including phenyl- and benzyl-thiazolylpiperidine derivatives, and pharmaceutically acceptable salts thereof, which are useful active ingredients for administration in a method for the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides methods for making such derivatives, and pharmaceutical compositions including such derivatives together with pharmaceutically acceptable excipients.

  该发明提供了噻唑基哌嗪衍生物，以及包括苯基和苄基噻唑基哌啶衍生物的N-磺酰杂环衍生物，以及其药学上可接受的盐，这些是用于治疗α-突触核蛋白病的有效活性成分，如帕金森病、弥漫性小体病、创伤性脑损伤、肌萎缩侧索硬化症、尼曼-匹克病、哈勒沃登-施帕茨综合征、唐氏综合征、神经轴突萎缩、多系统萎缩和阿尔茨海默病的治疗方法。该发明还提供了制备这些衍生物的方法，以及包括这些衍生物和药学上可接受的辅料的药物组合物。
• Design, synthesis and bioevaluation of 3-oxo-6-aryl-2,3-dihydropyridazine-4-carbohydrazide derivatives as novel xanthine oxidase inhibitors
  作者：Lichao Zhang、Sibo Wang、Mingzheng Yang、Ailong Shi、He Wang、Qi Guan、Kai Bao、Weige Zhang

  DOI：10.1016/j.bmc.2019.03.027

  日期：2019.5

  In view of expanding the structure activity relationship of xanthine oxidase inhibitors, a series of 3-oxo-6-aryl-2,3-dihydropyridazine-4-carbohydrazide/carboxylic acid derivatives were designed by molecular docking and synthesized. All the target compounds were evaluated for their in vitro XO inhibition by using febuxostat and allopurinol as the standard controls. Most of the hydrazide derivatives

  为了扩大黄嘌呤氧化酶抑制剂的结构活性关系，通过分子对接设计合成了一系列3-氧代-6-芳基-2,3-二氢哒嗪-4-羧酰肼/羧酸衍生物。使用非布索坦和别嘌呤醇作为标准对照，评估所有目标化合物的体外XO抑制作用。大多数酰肼衍生物表现出在微摩尔范围内的效力水平。从对接研究的角度来看，酰肼衍生物通过一种新颖的相互作用方式与XO的活性位点结合，这与带有羧基的非布索坦的相互作用方式不同。最有希望的化合物8b进一步进行动力学分析，以推论其抑制方式。